A Phase IIb, 24 Week, Randomized, Double-blind, 3 Arm Parallel Group Study, Comparing the Efficacy, Safety and Tolerability of Two Doses of Umeclidinium Bromide Administered Once-daily Via a Dry Powder Inhaler, Versus Placebo, in Participants With Asthma
Phase of Trial: Phase II
Latest Information Update: 13 Aug 2017
At a glance
- Drugs Umeclidinium (Primary) ; Fluticasone furoate; Salbutamol
- Indications Asthma
- Focus Therapeutic Use
- Sponsors GlaxoSmithKline
- 22 Jun 2017 Planned End Date changed from 22 Jan 2018 to 12 Jun 2018.
- 22 Jun 2017 Planned primary completion date changed from 22 Jan 2018 to 12 Jun 2018.
- 10 Apr 2017 Planned primary completion date changed from 25 Oct 2017 to 22 Jan 2018.